| Number of all screening smears (100%) |
166,010 |
165,818 |
160,949 |
158,017 |
156,144 |
155,697 |
158,678 |
141,696 |
158,590 |
155,300 |
| Satisfactory |
99.8% |
99.8% |
99.8% |
99.9% |
99.9% |
99.8% |
99.8% |
99.8% |
99.8% |
99.8% |
| Negative for intraepithelial lesion or malignancy |
90.8% |
91.2% |
90.4% |
90.6% |
90.4% |
90.1% |
89.1% |
89.0% |
89.5% |
89.6% |
| Non-neoplastic changes |
4.7% |
4.2% |
4.4% |
4.4% |
4.5% |
4.6% |
5.2% |
5.1% |
5.2% |
5.8% |
| Pathological changes |
4.3% |
4.5% |
5.1% |
4.9% |
4.9% |
5.1% |
5.5% |
5.7% |
5.1% |
4.4% |
| Pathological (squamous cells) |
4.2% |
4.4% |
4.9% |
4.8% |
4.8% |
5.0% |
5.4% |
5.6% |
5.0% |
4.3% |
| ASC-US |
2.4% |
2.7% |
2.8% |
2.9% |
2.9% |
3.0% |
3.3% |
3.5% |
3.2% |
2.7% |
| ASC-H |
0.2% |
0.2% |
0.3% |
0.3% |
0.3% |
0.3% |
0.3% |
0.3% |
0.3% |
0.3% |
| LSIL |
1.1% |
1.1% |
1.3% |
1.2% |
1.2% |
1.2% |
1.3% |
1.4% |
1.3% |
1.2% |
| HSIL |
0.4% |
0.5% |
0.5% |
0.5% |
0.4% |
0.4% |
0.5% |
0.4% |
0.4% |
0.2% |
| Squamous cell carcinoma |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
| Pathological (glandular cells) |
0.1% |
0.1% |
0.2% |
0.1% |
0.1% |
0.1% |
0.1% |
0.1% |
0.1% |
0.1% |
| AGC-NOS |
0.1% |
0.1% |
0.1% |
0.1% |
0.1% |
0.1% |
0.1% |
0.1% |
0.1% |
0.1% |
| AGC-favour neoplastic |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
| AIS |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
| Adenocarcinoma |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
| Other |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
| Suspicious cells, nonspecified |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
| Other malignant cells |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |